Por favor, use este identificador para citar o enlazar este documento:
https://hdl.handle.net/2445/179214
Título: | Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018) |
Autor: | Cantón, Rafael Loza, Elena Arcay, Ricardo M. Cercenado, Emilia Castillo, Francisco Javier Cisterna, Ramón Gálvez Benítez, Lidia González Romo, Fernando Hernández Cabezas, Alicia Rodríguez Lozano, Jesús Suárez Barrenechea, Ana Isabel Tubau, Fe Díaz Regañón, Jazmín López Mendoza, Diego SMART-Spain Working Group |
Materia: | Pseudomonas Resistència als medicaments Medicaments antibacterians Epidemiologia Pseudomonas Drug resistance Antibacterial agents Epidemiology |
Fecha de publicación: | 1-mar-2021 |
Publicado por: | Sociedad Española de Quimioterapia |
Resumen: | Objective: To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study. Methods: The susceptibility of 5,351 isolates collected in 11 Spanish hospitals (2016-2018) were analysed (EUCAST-2020 criteria) by broth microdilution and were phenotypically studied for the presence of extended-spectrum beta-lactamases (ESBL). Ceftolozane-tazobactam and/or carbapenem resistant isolates were genetically characterized for ESBL and carbapenemases. Results: Escherichia coli was the most frequent pathogen (49.3% IAI, 54.9% UTI, 16.7% RTI and 50% BSI), followed by Klebsiella pneumoniae (11.9%, 19.1%, 13.1% and 15.4%, respectively). P. aeruginosa was isolated in 9.3%, 5.6%, 32% and 9%, respectively. The frequency of isolates with ESBLs (2016-2017) was: 30.5% K. pneumoniae, 8.6% E. coli, 2.3% Klebsiella oxytoca and 0.7% Proteus mirabilis. Ceftolozane-tazobactam was very active against non-ESBL-(99.3% susceptible) and ESBL-(95.2%) producing E. coli being less active against K. pneumoniae (98% and 43.1%, respectively) isolates. CTX-M-15 was the most prevalent ESBL in E. coli (27.5%) and K. pneumoniae (51.9%) frequently associated with OXA-48-like carbapenemase. Overall, 93% of P. aeruginosa isolates were susceptible to ceftolozane-tazobactam, preserving this activity (>75%) in isolates resistant to other beta-lactams except in those resistant to meropenen or ceftazidime-avibactam. GES-5, PER-1, VIM-1/2 were the most prevalent enzymes in isolates resistant to ceftolozane-tazobactam. Conclusions: Ceftolozane-tazobactam showed high activity rates against isolates recovered in the SMART study although it was affected in K. pneumoniae and P. aeruginosa isolates with ESBL and/or carbapenemases. |
Nota: | Reproducció del document publicat a: https://doi.org/10.37201/req/019.2021 |
Es parte de: | Revista Española de Quimioterapia, 2021, vol. 34, num. 3, p. 228-237 |
URI: | https://hdl.handle.net/2445/179214 |
Recurso relacionado: | https://doi.org/10.37201/req/019.2021 |
ISSN: | 0214-3429 |
Aparece en las colecciones: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Archivos de este documento:
Archivo | Descripción | Dimensiones | Formato | |
---|---|---|---|---|
canton01mar2021.pdf | 493.5 kB | Adobe PDF | Mostrar/Abrir |
Este documento está sujeto a una
Licencia Creative Commons